Enliven Therapeutics' Soaring Stock Faces a $570,000 Insider Reality Check

Related Articles

Costco's Unyielding Valuation Faces a Margin Reality Check

2 months ago

Personalis's Clinical Growth Story Faces a Reality Check as CEO Sells Millions

2 months ago

The Olaf Incident: A Chilling Reality Check for AI

5 months ago

OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

2 months ago

Category

You may also like

Stock News•2 weeks ago

As Lumentum Stock Soars, a Company Insider Dumps Nearly 40,000 Shares Worth $33 Million

Lumentum stock soared as an insider sold 38,663 shares for ~$33.0 million, equal to 33% of the direct stake held before the filing, per the transaction date's weighted average price.

LITE

Share

Stock News•3 weeks ago

Director's Confidence Visible as Elanco Leader Buys 10,000 Shares

An Elanco director raised their stake by 10,000 shares, increasing direct equity holdings by 10%, signaling insider confidence in the company's outlook.

ELAN

Share

Stock News•2 months ago

Kymera's CEO Sold $6 Million in Stock After a 170% Run

Kymera CEO sold ~$6M in stock after a 170% run, exercising 50,000 shares at $119 on July 7. The sale reduced direct holdings by 7%.

KYMR

Share